Cited by 1,336Renal cell carcinoma treatmentCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

Open access

The Cancer Genome Atlas Research Network·2016·New England Journal of Medicine

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1505917

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citation
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citation
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635

Show all 42 references

Research works printed but not linked: 2

Delahunt B, 1997, Mod Pathol, 10, 537
Schmidt LS, 1998, Cancer Res, 58, 1719

Sorted by citations

Items 201–300 of 1,000

Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Mehdi, A., & Riazalhosseini, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081774 · Cited by 68
Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions
Rathmell, W. K., Rathmell, J. C., & Linehan, W. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2309 · Cited by 68
The prospect of precision therapy for renal cell carcinoma
Ciccarese, C., Brunelli, M., Montironi, R., Fiorentino, M., Iacovelli, R., Heng, D. Y. C., Tortora, G., & Massari, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.003 · Cited by 68
From kidney injury to kidney cancer
Peired, A. J., Lazzeri, E., Guzzi, F., Anders, H., & Romagnani, P. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.011 · Cited by 64
Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma
Qamra, A., Xing, M., Padmanabhan, N., Kwok, J. J. T., Zhang, S., Xu, C., Leong, Y. S., Lim, A. P. L., Tang, Q., Ooi, W. F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1022 · Cited by 64
What’s new in the WHO 2022 classification of kidney tumours?
Alaghehbandan, R., Siadat, F., & Trpkov, K. (2023) · Pathologica · doi:10.32074/1591-951x-818 · Cited by 62
TFEB Expression Profiling in Renal Cell Carcinomas
Gupta, S., Argani, P., Jungbluth, A. A., Chen, Y., Tickoo, S. K., Fine, S. W., Gopalan, A., Al‐Ahmadie, H. A., Sirintrapun, S. J., Sánchez, A., et al. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001307 · Cited by 62
Machine learning analysis of TCGA cancer data
Liñares-Blanco, J., Pazos, A., & Fernandez-Lozano, C. (2021) · PeerJ Computer Science · doi:10.7717/peerj-cs.584 · Cited by 63
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions
Purdue, M. P., Dutta, D., Machiela, M. J., Gorman, B. R., Winter, T., Okuhara, D. Y., Cleland, S., Ferreiro-Iglesias, A., Scheet, P. A., Liu, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01725-7 · Cited by 60
Renal tumors in end‐stage renal disease: A comprehensive review
Tsuzuki, T., Iwata, H., Murase, Y., Takahara, T., & Ohashi, A. (2018) · International Journal of Urology · doi:10.1111/iju.13759 · Cited by 62
Non–Clear Cell Renal Cell Carcinomas: From Shadow to Light
Albiges, L. K., Flippot, R., Rioux-Leclercq, N. C., & Choueiri, T. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2531 · Cited by 60
Renal Tumors of Childhood—A Histopathologic Pattern-Based Diagnostic Approach
Ooms, A. H. A. G., Vujanic, G. M., D’Hooghe, E., Collini, P., L’Herminé, A. C., Vokuhl, C., Graf, N. M., van den Heuvel‐Eibrink, M. M., & de Krijger, R. R. (2020) · Cancers · doi:10.3390/cancers12030729 · Cited by 59
Roles of MET in human cancer
Yang, X. L., Liao, H.-Y., & Zhang, H. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.017 · Cited by 59
A renal cell carcinoma tumorgraft platform to advance precision medicine
Elias, R. M., Tcheuyap, V. T., Kaushik, A., Singla, N., Gao, M., Reig, Ò., Christie, A. L., Mulgaonkar, A., Woolford, L., Stevens, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110055 · Cited by 61
Metabolic features of cancer cells in NRF2 addiction status
Okazaki, K., Papagiannakopoulos, T., & Motohashi, H. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00659-8 · Cited by 57
Papillary renal cell carcinoma: current and controversial issues
Angori, S., Lobo, J., & Moch, H. (2022) · Current Opinion in Urology · doi:10.1097/mou.0000000000001000 · Cited by 59
Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features
Inamura, K. (2017) · Cancers · doi:10.3390/cancers9090111 · Cited by 58
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options
Ahrens, M., Scheich, S., Hartmann, A., Bergmann, L., & IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society (2019) · Oncology Research and Treatment · doi:10.1159/000495366 · Cited by 57
A comparison of the prognosis of papillary and clear cell renal cell carcinoma
Deng, J., Li, L., Xia, H., Guo, J., Wu, X. Y., Yang, X., Hong, Y., Chen, Q., & Hu, J. (2019) · Medicine · doi:10.1097/md.0000000000016309 · Cited by 57
Clinical use of a machine learning histopathological image signature in diagnosis and survival prediction of clear cell renal cell carcinoma
Chen, S., Zhang, N., Jiang, L., Gao, F., Shao, J., Wang, T., Zhang, E., Yu, H., Wang, X., & Zheng, J. (2020) · International Journal of Cancer · doi:10.1002/ijc.33288 · Cited by 57
TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma
Wang, X. M., Zhang, Y., Mannan, R., Skala, S. L., Rangaswamy, R., Chinnaiyan, A. K., Su, F., Cao, X., Zelenka-Wang, S., McMurry, L. M., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00803-z · Cited by 59
The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols
Daugherty, M. R., Sedaghatpour, D., Shapiro, O., Vourganti, S., Kutikov, A., & Bratslavsky, G. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.11.009 · Cited by 56
Significant associations between driver gene mutations and DNA methylation alterations across many cancer types
Chen, Y.-C., Gotea, V., Margolin, G., & Elnitski, L. L. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005840 · Cited by 56
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
Négrier, S., Rioux-Leclercq, N. C., Ferlay, C., Gross‐Goupil, M., Gravis, G., Geoffrois, L., Chevreau, C., Boyle, H. J., Rolland, F., Blanc, E., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.001 · Cited by 56
TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1
Caliò, A., Harada, S., Brunelli, M., Pedron, S., Segala, D., Cañete‐Portillo, S., Magi‐Galluzzi, C., Netto, G. J., Mackinnon, A. C., & Martignoni, G. (2020) · Modern Pathology · doi:10.1038/s41379-020-00713-6 · Cited by 55
Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas
Malouf, G. G., Compérat, É., Yao, H., Mouawad, R., Lindner, V., Rioux-Leclercq, N. C., Verkarre, V., Leroy, X., Dainese, L., Classe, M., et al. (2016) · Scientific Reports · doi:10.1038/srep30988 · Cited by 56
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study
Buti, S., Bersanelli, M., Maines, F., Facchini, G., Gelsomino, F., Zustovich, F., Santoni, M., Verri, E., Giorgi, U. D., Masini, C., et al. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.12.024 · Cited by 55
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Tannir, N. M., Schwab, G. M., & Grünwald, V. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0566-9 · Cited by 55
Renal cell carcinoma: new insights and challenges for a clinician scientist
Shingarev, R. A., & Jaimes, E. A. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00480.2016 · Cited by 57
Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management
Herrera-Caceres, J. O., Finelli, A., & Jewett, M. A. S. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2373-9 · Cited by 55
Therapeutic Applications of Human and Bovine Colostrum in the Treatment of Gastrointestinal Diseases and Distinctive Cancer Types: The Current Evidence
Bagwe‐Parab, S., Yadav, P., Kaur, G., Tuli, H. S., & Buttar, H. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01100 · Cited by 54
Metabolic alterations in hereditary and sporadic renal cell carcinoma
Coffey, N. J., & Simon, M. C. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00800-2 · Cited by 56
Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC
Xia, Q., Wang, X., Zhan, X., Tan, X., Chen, H., Liu, Y., Shi, S., Wang, X., Wei, X., Ye, S., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000837 · Cited by 54
Pan-urologic cancer genomic subtypes that transcend tissue of origin
Chen, F., Zhang, Y., Bossé, D., Lalani, A. A., Hakimi, A. A., Hsieh, J. J.-D., Choueiri, T. K., Gibbons, D. L., Ittmann, M., & Creighton, C. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00289-x · Cited by 57
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets
Caliò, A., Brunelli, M., Segala, D., Pedron, S., Remo, A., Ammendola, S., Munari, E., Pierconti, F., Mosca, A., Bollito, E., et al. (2020) · Pathology · doi:10.1016/j.pathol.2019.11.006 · Cited by 54
Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations
Li, S., Shuch, B. M., & Gerstein, M. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006685 · Cited by 53
Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice
Casuscelli, J., Vano, Y. A., Fridman, W. H., & Hsieh, J. J.-D. (2017) · Kidney Cancer · doi:10.3233/kca-170008 · Cited by 58
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Jiang, W., & Ji, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.006 · Cited by 55
Chimeric RNAs in cancer
Shi, X., Singh, S., Lin, E., & Li, H. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.04.001 · Cited by 52
Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer
Hsieh, J. J.-D., Manley, B. J., Khan, N. A., Gao, J., Carlo, M. I., & Cheng, E. H. Y. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.002 · Cited by 54
Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma
Larrabeiti-Etxebarria, A., López-Santillán, M., Santos‐Zorrozúa, B., López-López, E., & García‐Orad, Á. (2019) · Cancers · doi:10.3390/cancers11020144 · Cited by 52
High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis
Yang, C., Shuch, B. M., Kluger, H. M., Humphrey, P. A., & Adeniran, A. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001455 · Cited by 52
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers
Sourbier, C., Liao, P., Ricketts, C. J., Wei, D., Yang, Y., Baranes, S. M., Gibbs, B. K., Ohanjanian, L., Krane, L. S., Scroggins, B. T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24112 · Cited by 52
Clear cell carcinomas of the ovary and kidney: clarity through genomics
Ji, J. X. Y., Wang, Y. K., Cochrane, D. R., & Huntsman, D. D. (2018) · The Journal of Pathology · doi:10.1002/path.5037 · Cited by 52
Comprehensive analysis of ferritin subunits expression and positive correlations with tumor-associated macrophages and T regulatory cells infiltration in most solid tumors
Hu, Z., Chen, L., Ma, R., Wei, F., Wen, Y., Zeng, X., Sun, W., & Wen, W. (2021) · Aging · doi:10.18632/aging.202841 · Cited by 52
Chameleon TFE3-translocation RCC and How Gene Partners Can Change Morphology: Accurate Diagnosis Using Contemporary Modalities
Tretiakova, M. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000332 · Cited by 50
French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer
Bigot, P., Barthélémy, P., Boissier, R., Khene, Z., Pettenati, C., Bernhard, J., Corréas, J.-M., Doumerc, N., Gimel, P., Ingels, A., et al. (2022) · The French Journal of Urology · doi:10.1016/j.purol.2022.07.146 · Cited by 52
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy
Pilotto, S., Γκουντάκος, Α., Carbognin, L., Scarpa, A., Tortora, G., & Bria, E. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.33 · Cited by 50
The Identification of Immunological Biomarkers in Kidney Cancers
Antonio Lopez-beltran, B., Henriques, V., Cimadamore, A., Santoni, M., Liang Cheng, C., Gevaert, T., Blanca, A., Massari, F., Scarpelli, M., & Montironi, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00456 · Cited by 52
Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile
Sarungbam, J., Mehra, R., Tomlins, S. A., Smith, S. C., Jayakumaran, G., Al‐Ahmadie, H. A., Gopalan, A., Sirintrapun, S. J., Fine, S. W., Zhang, Y., et al. (2019) · Modern Pathology · doi:10.1038/s41379-018-0185-5 · Cited by 50
Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review
Cimadamore, A., Liang Cheng, C., Scarpelli, M., Massari, F., Mollica, V., Santoni, M., Antonio Lopez-beltran, B., Montironi, R., & Moch, H. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1150 · Cited by 50
Nrf2 Signaling in Renal Cell Carcinoma: A Potential Candidate for the Development of Novel Therapeutic Strategies
Schiavoni, V., Emanuelli, M., Milanese, G., Galosi, A. B., Pompei, V., Salvolini, E., & Campagna, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413239 · Cited by 51
VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney
Wang, L., Zhang, Y., Chen, Y., Skala, S. L., Al‐Ahmadie, H. A., Wang, X., Cao, X., Veeneman, B. A., Chen, J., Cieslik, M. P., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001150 · Cited by 52
Lysine methyltransferase inhibitors: where we are now
Feoli, A., Viviano, M., Cipriano, A., Milite, C., Castellano, S., & Sbardella, G. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00196e · Cited by 50
Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
Tjota, M. Y., Segal, J. P., & Wang, P. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad091 · Cited by 49
Comprehensive proteogenomic characterization of rare kidney tumors
Li, G. X., Chen, L., Hsiao, Y., Mannan, R., Zhang, Y., Luo, J., Petralia, F., Cho, H., Hosseini, N., Leprevost, F. D. V., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101547 · Cited by 52
Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials
de Velasco, G., McKay, R. R., Lin, X., Moreira, R. B., Simantov, R., & Choueiri, T. K. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.03.004 · Cited by 49
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Graham, J., Wells, J. C., Donskov, F. N., Lee, J., Fraccon, A. P., Pasini, F., Porta, C., Bowman, I. A., Bjarnason, G. A., Ernst, D. S., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.03.007 · Cited by 48
Genomics and clinical correlates of renal cell carcinoma
Mitchell, T. J., Rossi, S. H., Klatte, T., & Stewart, G. D. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2429-x · Cited by 49
Significance of KDM6A mutation in bladder cancer immune escape
Chen, X., Lin, X., Pang, G., Deng, J., Xie, Q., & Zhang, Z. (2021) · BMC Cancer · doi:10.1186/s12885-021-08372-9 · Cited by 48
Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma
Wang, Q., Zhang, Y., Zhang, B., Fu, Y. S., Zhao, X., Zhang, J., Zuo, K., Xing, Y., Jiang, S., Qin, Z. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27660-3 · Cited by 50
MicroRNAs in biofluids are novel tools for bladder cancer screening
Liu, X., Liu, X., Wu, Y., Wu, Q., Wang, Q., Yang, Z., & Li, L. (2017) · Oncotarget · doi:10.18632/oncotarget.16026 · Cited by 47
Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
Carril-Ajuria, L., Colomba, É., Cerbone, L., Romero, C., Crouzet, L., Laguerre, B., Thibault, C., Vicier, C., de Velasco, G., Fléchon, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.009 · Cited by 47
Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein
Laviolette, L. A., Mermoud, J., Calvo, I. A., Olson, N., Boukhali, M., Steinlein, O. K., Roider, E., Sattler, E., Huang, D., Teh, B. T., et al. (2017) · Nature Communications · doi:10.1038/ncomms15866 · Cited by 47
Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features
Ren, Q., Wang, L., Al‐Ahmadie, H. A., Fine, S. W., Gopalan, A., Sirintrapun, S. J., Tickoo, S. K., Reuter, V. E., & Chen, Y. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001038 · Cited by 47
Gene fusion analysis in renal cell carcinoma by FusionPlex RNA‐sequencing and correlations of molecular findings with clinicopathological features
Tretiakova, M., Wang, W., Wu, Y., Tykodi, S. S., True, L. D., & Liu, Y. J. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22798 · Cited by 47
Clinicopathological and molecular characterisation of papillary renal neoplasm with reverse polarity and its renal papillary adenoma analogue
Chang, H., Hang, J., Wu, C., Lin, T., Chung, H., Chang, Y., & Pan, C. (2020) · Histopathology · doi:10.1111/his.14320 · Cited by 47
Subgroup-Independent Mapping of Renal Cell Carcinoma—Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries
Marquardt, A., Solimando, A. G., Kerscher, A., Bittrich, M., Kalogirou, C., Kübler, H. R., Rosenwald, A., Bargou, R. C., Kollmannsberger, P., Schilling, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621278 · Cited by 48
A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma
Gao, Z., Zhang, D., Duan, Y., Yan, L., Fan, Y., Fang, Z., & Liu, Z. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211491 · Cited by 46
MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition
Macháčková, T., Mlčochová, H., Staník, M., Doležel, J., Fedorko, M., Pacík, D., Poprach, A., Svoboda, M., & Slabý, O. (2016) · Tumor Biology · doi:10.1007/s13277-016-5310-9 · Cited by 46
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy
Massari, F., Nunno, V. D., Gatto, L., Santoni, M., Schiavina, R., Cosmai, L., Brunocilla, E., Ardizzoni, A., & Porta, C. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0601-2 · Cited by 46
Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity
Kiyozawa, D., Kohashi, K., Takamatsu, D., Yamamoto, T., Eto, M., Iwasaki, T., Motoshita, J., Shimokama, T., Kinjo, M., Oshiro, Y., et al. (2021) · Human Pathology · doi:10.1016/j.humpath.2021.03.009 · Cited by 46
Tissue-specific DNA methylation loss during ageing and carcinogenesis is linked to chromosome structure, replication timing and cell division rates
Dmitrijeva, M., Ossowski, S., Serrano, L. G., & Schaefer, M. H. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky498 · Cited by 54
Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer
Shuch, B. M., Li, S., Risch, H. A., Bindra, R. S., McGillivray, P. D., & Gerstein, M. (2020) · Cancer · doi:10.1002/cncr.32914 · Cited by 45
MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights
Simonaggio, A., Ambrosetti, D., Verkarre, V., Auvray, M., Oudard, S. M., & Vano, Y. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147649 · Cited by 44
Recommendations for the Management of Rare Kidney Cancers
Giles, R. H., Choueiri, T. K., Heng, D. Y. C., Albiges, L. K., Hsieh, J. J.-D., Linehan, W. M., Pal, S. K., Maskens, D. A., Paseman, B., Jonasch, E. W., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.040 · Cited by 44
Papillary Renal Neoplasm With Reverse Polarity: A Clinicopathologic Study of 7 Cases
Zhou, L., Xu, J., Wang, S., Yang, X., Li, C., Zhou, J., Zhang, P., Xu, H., & Wang, C. (2020) · International Journal of Surgical Pathology · doi:10.1177/1066896920918289 · Cited by 44
Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome
Murugan, P. J., Jia, L., DiNatale, R. G., Assel, M. J., Benfante, N. E., Al‐Ahmadie, H. A., Fine, S. W., Gopalan, A., Sarungbam, J., Sirintrapun, S. J., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00990-9 · Cited by 44
Neoplasms of the Kidney
MacLennan, G. T., & Liang Cheng, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-23380-2_35 · Cited by 43
Characterizing the outcomes of metastatic papillary renal cell carcinoma
Wells, J. C., Donskov, F. N., Fraccon, A. P., Pasini, F., Bjarnason, G. A., Beuselinck, B., Knox, J. J., Rha, S. Y., Agarwal, N., Bowman, I. A., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1048 · Cited by 43
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies
Ciccarese, C., Iacovelli, R., Brunelli, M., Massari, F., Bimbatti, D., Fantinel, E., MARCO, V. D., Porcaro, A. B., Martignoni, G., Artibani, W., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.030 · Cited by 43
Papillary renal cell carcinoma-derived chemerin, IL-8, and CXCL16 promote monocyte recruitment and differentiation into foam-cell macrophages
Krawczyk, K. M., Nilsson, H., Allaoui, R., Lindgren, D., Arvidsson, M., Leandersson, K., & Johansson, M. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.78 · Cited by 43
Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors
Tuna, M., Amos, C. I., & Mills, G. B. (2019) · Oncotarget · doi:10.18632/oncotarget.26777 · Cited by 47
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology
Reardon, B. M., Moore, N. D., Moore, N., Kofman, E. R., AlDubayan, S. H., Cheung, A. T. M., Conway, J. R., Elmarakeby, H., Imamović, A., Kamran, S. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00243-3 · Cited by 43
Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma
Weaver, C., Satter, K. B., Richardson, K. P., Tran, L. K. H., Tran, P. M. H., & Purohit, S. B. (2022) · Biomedicines · doi:10.3390/biomedicines10112953 · Cited by 48
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
Twardowski, P. W., Tangen, C. M., Wu, X., Plets, M., Plimack, E. R., Agarwal, N., Vogelzang, N. J., Wang, J., Tao, S., Thompson, I. M., et al. (2017) · Kidney Cancer · doi:10.3233/kca-170018 · Cited by 42
Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article
Pitra, T., Pivovarčíková, K., Alaghehbandan, R., & Hes, O. (2017) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2017.11.004 · Cited by 42
TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms
Caliò, A., Marletta, S., Brunelli, M., Pedron, S., Cañete‐Portillo, S., Segala, D., Bariani, E., Gobbo, S., Netto, G. J., & Martignoni, G. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03380-x · Cited by 41
Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas
Haake, S. M., Weyandt, J. D., & Rathmell, W. K. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0115 · Cited by 41
Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease
Wagener, N., Edelmann, D., Benner, A., Zigeuner, R. E., Borgmann, H., Wolff, I., Krabbe, L. M., Musquera, M., Dell’Oglio, P., Umberto Capitanio, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184173 · Cited by 41
A comparison of mechanistic signaling pathway activity analysis methods
Amadoz, A., Hidalgo, M. R., Çubuk, C., Carbonell‐Caballero, J., & Dopazo, J. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby040 · Cited by 41
Transcriptome-wide mapping reveals a diverse dihydrouridine landscape including mRNA
Draycott, A. S., Schaening-Burgos, C., Rojas-Durán, M. F., Wilson, L., Schärfen, L., Neugebauer, K. M., Nachtergaele, S., & Gilbert, W. V. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001622 · Cited by 45
Prostate cancer reshapes the secreted and extracellular vesicle urinary proteomes
Khoo, A., Govindarajan, M., Qiu, Z., Liu, L. Y., Ignatchenko, V., Waas, M., Macklin, A., Keszei, A., Neu, S., Main, B. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49424-5 · Cited by 40
Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?
Haake, S. M., & Rathmell, W. K. (2016) · Cancer · doi:10.1002/cncr.30314 · Cited by 42
Systemic Therapy for Non–Clear Cell Renal Cell Carcinoma
Zhang, T., Gong, J., Maia, M. C., & Pal, S. K. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175572 · Cited by 40
The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians
Jones, J. M., Bhatt, J. R., Avery, J., Laupacis, A., Cowan, K., Basappa, N. S., Basiuk, J., Canil, C., Al-Asaaed, S., Heng, D. Y. C., et al. (2017) · Canadian Urological Association Journal · doi:10.5489/cuaj.4590 · Cited by 40
Network Analysis as a Grand Unifier in Biomedical Data Science
McGillivray, P. D., Clarke, D., Meyerson, W. U., Zhang, J., Lee, D., Gu, M., Kumar, S., Zhou, H., & Gerstein, M. (2018) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-080917-013444 · Cited by 41
A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non–clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
Park, I., Lee, S., & Lee, J. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.05.011 · Cited by 40
Lysosomes contribute to radioresistance in cancer
Zhang, X., Wang, J., Li, X., & Wang, D. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.029 · Cited by 40
ALK Fusions in Renal Cell Carcinoma: Response to Entrectinib
Tao, J. J., Ge, W., Patel, R., Fagan, P. C., Hao, X., Bridge, J. A., Arcila, M. E., Al‐Ahmadie, H. A., Lee, C., Li, G., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00185 · Cited by 40

Authors: The Cancer Genome Atlas Research Network
Affiliations: National Institutes of Health (US)
Corresponding author: The Cancer Genome Atlas Research Network
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-01-14
Volume: 374
Issue: 2
Pages: 135-145
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1505917
PMC: PMC4775252
OpenAlex: W2111867681
Cited by: 1,336
References: 42
Citations by year: 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
FWCI: 92.55
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health (UL1TR000005)
National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
MeSH terms: Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks